Carla L Alves
Overview
Explore the profile of Carla L Alves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kindt C, Ehmsen S, Traynor S, Policastro B, Nissen N, Jakobsen M, et al.
Front Oncol
. 2025 Feb;
14:1497093.
PMID: 39931212
Background: Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer. However, resistance to this treatment and disease progression remains...
2.
Kindt C, Alves C, Ehmsen S, Kragh A, Reinert T, Vogsen M, et al.
Int J Cancer
. 2024 Aug;
155(12):2211-2222.
PMID: 39128978
Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improves outcome for patients with estrogen receptor-positive (ER+) metastatic breast cancer, but drug resistance and thus disease progression inevitably occur. Herein, we...
3.
Karimi L, Alves C, Terp M, Tuttolomondo M, Portman N, Ehmsen S, et al.
Cancer Commun (Lond)
. 2023 Apr;
43(6):720-725.
PMID: 37101393
No abstract available.
4.
Alves C, Ditzel H
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36901954
The frequent activation of the PI3K/AKT/mTOR pathway and its crucial role in estrogen receptor-positive (ER+) breast cancer tumorigenesis and drug resistance has made it a highly attractive therapeutic target in...
5.
Al-Qasem A, Alves C, Ehmsen S, Tuttolomondo M, Terp M, Johansen L, et al.
NPJ Precis Oncol
. 2022 Sep;
6(1):68.
PMID: 36153348
Resistance to aromatase inhibitor (AI) treatment and combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) are crucial clinical challenges in treating estrogen receptor-positive (ER+) breast cancer. Understanding the resistance mechanisms...
6.
Skov N, Alves C, Ehmsen S, Ditzel H
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077449
Triple-negative breast cancer (TNBC) is a heterogeneous disease that accounts for 10-15% of all breast cancer cases. Within TNBC, the treatment of basal B is the most challenging due to...
7.
Al-Qasem A, Alves C, Ditzel H
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771560
The introduction of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) has revolutionized the treatment landscape for patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) and has become...
8.
Alves C, Ehmsen S, Terp M, Portman N, Tuttolomondo M, Gammelgaard O, et al.
Nat Commun
. 2021 Sep;
12(1):5588.
PMID: 34531405
No abstract available.
9.
Alves C, Ehmsen S, Terp M, Portman N, Tuttolomondo M, Gammelgaard O, et al.
Nat Commun
. 2021 Aug;
12(1):5112.
PMID: 34433817
CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most patients will eventually experience disease progression on this combination, underscoring the...
10.
Kaminska K, Akrap N, Staaf J, Alves C, Ehinger A, Ebbesson A, et al.
Breast Cancer Res
. 2021 Feb;
23(1):26.
PMID: 33602273
Background: Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are...